Akums Drugs & Pharmaceuticals IPO Details
| IPO Size | 1856.74 |
| Price Range | ₹646 - ₹679 |
| Retail Quota | 10% |
| QIB Quota | 75% |
| NII Quota | 15% |
| Employee Discount | ₹64 per share |
| Listing at | NSE and BSE |
| Minimum Quantity | 22 |
| Investment (cut-off price) | ₹14,938 |
| Pre IPO Promotor Holding | 84.94% |
| Post IPO Promotor Holding | -- |
| DHRP Draft | Click Here |
| RHP Draft | Click Here |
| Anchor Investors List | Click Here |
Akums Drugs & Pharmaceuticals IPO Timelines
30/07/2024
Start Date01/08/2024
End Date05/08/2024
Refund Initiation05/08/2024
Credit of Shares to Demat Ac06/08/2024
Listing DateAkums Drugs & Pharmaceuticals IPO Lot Size
| Application | Lot Size | Shares | Amount |
|---|---|---|---|
| Retail Minimum | 1 | 22 | ₹14,938 |
| Retail Maximum | 13 | 286 | ₹194,194 |
| S-HNI Minimum | 14 | 308 | ₹209,132 |
| B-HNI Minimum | 67 | 1474 | ₹1,000,846 |
Akums Drugs & Pharmaceuticals IPO Subscription Status
| QIB | NII | Retail | EMP | Total |
|---|---|---|---|---|
| 90.09 x | 42.21 x | 21.30 x | 4.27 x | 63.56 x |
IPO Performance on Listing Day
| Opening Price | Closing Price | Day High | Day Low |
|---|---|---|---|
| ₹725 | ₹796.25 | ₹797.50 | ₹725 |
Akums Drugs & Pharmaceuticals IPO Company Financials
| Year | Total Income | Total Expense | PAT |
|---|---|---|---|
| FY 2022 | ₹3694.52 | ₹3874.95 | ₹-250.87 |
| FY 2023 | ₹3700.93 | ₹3475.93 | ₹97.82 |
| FY 2024 | ₹4212.21 | ₹4231.45 | ₹0.79 |
About Company
Akums Drugs and Pharmaceuticals Limited, established in 2004, is a leading pharmaceutical contract development and manufacturing organization (CDMO) providing a comprehensive range of products and services in India and internationally.
The company offers end-to-end solutions for product development, manufacturing, research and development (R&D) of formulations, regulatory dossier preparation, and submission, along with other testing services. Akums is also involved in the manufacture and sale of branded drugs and active pharmaceutical ingredients (APIs).
As a CDMO, Akums produces a variety of dosage forms, including tablets, capsules, liquid medicines, vials, ampoules, blow-filled closures, topical preparations, eye drops, dry powder injections, and gummy bears. The company has commercialised 4,025 formulations in over 60 dosage forms and, in 2023, manufactured formulations for 26 of India’s top 30 pharmaceutical companies by revenue. Akums operates 10 manufacturing units with a cumulative production capacity of 49.21 billion units annually as of September 30, 2023.
Plans for expansion include two additional production units set to be commissioned in FY 2025. Some of Akums’ facilities are accredited by global regulatory bodies such as EU-GMP, WHO-GMP, and US NSF. The company employs 16,463 individuals, comprising 7,211 full-time and 9,252 contract employees, as of September 30, 2023.
| Incorporation Date | Sector | Managing Director |
|---|---|---|
| 2004 | Healthcare | Sanjeev Jain |
Know Before Investing
Akums Drugs & Pharmaceuticals IPO Strengths
- Largest India-focused CDMO by revenue, production capacity, and clients (2023).
- Operates 12 manufacturing units with 49.23 billion units annual capacity.
- Manufactured 4,146 commercialised formulations across over 60 dosage forms.
- Market share of 30.2% in the Indian CDMO market (2024).
- Accredited by EU-GMP, WHO-GMP, and US NSF regulatory agencies.
- Robust client base with 1,524 pharmaceutical and wellness companies (2024).
- Achieved 10.79% CDMO revenue growth CAGR (2022-2024).
- Operates four dedicated R&D units with 406 scientists (2024).
Akums Drugs & Pharmaceuticals IPO Risks
- Concentration of manufacturing units in Uttarakhand exposes geographical risks.
- Business depends on uninterrupted operation of manufacturing and R&D units.
- Regulatory compliance and quality control are critical for operations.
- Relying on third-party suppliers for raw materials may cause disruptions.
- Supply chain disruptions from China could affect raw material availability.
- High costs and risks associated with new product development delays.
- Past non-compliance with Companies Act may lead to regulatory actions.
Swot Analysis for Akums Drugs & Pharmaceuticals IPO
Strengths
Marquee client Experienced promoter group
Weaknesses
Volatile margins on account of put option liability
Opportunities
Foray into new business segments New product launches
Threats
High competition from both domestic and global players
Company Details
Akums Drugs and Pharmaceuticals Limited
304, Mohan Place,
LSC Saraswati Vihar,
Delhi – 110 034
Phone: +91 11 6904 1000
Email: [email protected]
Website: http://www.akums.in/
IPO Registar Details
Link Intime India Private Ltd
Phone: +91-22-4918 6270
Email: [email protected]
Website: https://linkintime.co.in/initial_offer/public-issues.html
FAQs
The key objectives of Akums Drugs & Pharmaceuticals IPO are:
- Repayment/ prepayment of indebtedness of the company and its subsidiaries.
- Repayment/ prepayment of indebtedness of the Subsidiaries, namely, Maxcure Nutravedics Limited and Pure and Cure Healthcare Private Limited
- Funding incremental working capital requirements of the company.
- Pursuing inorganic growth initiatives through acquisitions.
- General corporate purposes.